Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 44 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Master Protocol to Compare MTX/5-FU vs CACP/5-FU vs Phase II Agent for Squamous Cell Cancer of the Head and Neck (Summary last modified 06/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-8223/24/25 SWOG-8224, SWOG-8225


2.		Phase II/III Chemotherapy with ADR vs DHAD vs ADC for Breast Cancer Not Previously Exposed to Intercalating Agents

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				no age specified				NCI				SWOG-8203/04 SWOG-8204


3.		Phase III Single-Agent Chemotherapy with Best Drug Selected by Clinician vs Best Selected by Capillary Cloning System for Disseminated, Refractory Breast, Ovarian, non-Small Cell and Small Cell Lung, Colon, and Renal Cancer and Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI				UTHSC-82305155 NCI-T85-0023W, T85-0023


4.		Phase I-II Chemotherapy with ADC for Refractory Adult Acute Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 15								UMCC-8103

Last Modified: 10/26/2007


5.		Phase I/II Mitoxantrone by Hepatic Arterial Infusion for Primary or Metastatic Hepatic Tumor Refractory to All Known Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				over 18								UTHSC-82305005 CTEPIS-0146, NCI-W83-0089, W83-0089


6.		Phase II Single-Agent Master Protocol for Advanced, Unresectable non-Small Cell Bronchogenic Carcinoma --- ADC (CL 216,942)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified								NCI-D81-012-538 ICC-81L1


7.		Master Protocol for Phase II Chemotherapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck --- ADC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified								NCI-D82-070-646 WRAMC-8205


8.		Phase II Chemotherapy with ADC on a Single-Dose Schedule for Advanced Renal Cell Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				no age specified								UMCC-8031


9.		Phase II Chemotherapy with CL 216,942 in Women with Advanced Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 18								UTHSC-BR-1


10.		Master Protocol for Phase II Chemotherapy for Advanced or Metastatic non-Small Cell Lung Carcinoma --- ADC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				over 16				NCI				CLB-8141

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute